PAUL P. CARBONE, M.D.; J. H. TJIO, M.D.; JACQUELINE WHANG, M.D.; JEROME B. BLOCK, M.D.; WILLIAM B. KREMER, M.D.; EMIL FREI III, M.D.
Chemotherapy or X irradiation produces improvement in the clinical and hematologic abnormalities in the majority of patients with chronic myelogenous leukemia (CML) (1-5). Return of the leukocyte alkaline phosphatase (LAP) and bone marrow morphology toward normal has been described but is less frequent (6-11). Recently, Tough and co-workers (12) have reported that the chromosome abnormality (Ph1) which is present in the majority of patients with CML disappears from the peripheral blood but not from the marrow after splenic X irradiation. The present study was designed to determine the relative frequency and magnitude of response of clinical, hematologic, and cytogenetic abnormalities
Learn more about subscription options.
Register Now for a free account.
CARBONE PP, TJIO JH, WHANG J, BLOCK JB, KREMER WB, FREI E. The Effect of Treatment in Patients with Chronic Myelogenous Leukemia: Hematologic and Cytogenetic Studies. Ann Intern Med. 1963;59:622–628. doi: 10.7326/0003-4819-59-5-622
Download citation file:
Published: Ann Intern Med. 1963;59(5_Part_1):622-628.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only